J&J Forecasts Sales of $3.5 Billion for Its COVID-19 Jab in 2022
Though it’s the least-administered COVID-19 vaccine of the three approved in the U.S., Johnson & Johnson (J&J) said it believes global sales of its COVID-19 vaccine will reach $3.5 billion in 2022.
That would represent an almost 50 percent spike over 2021, during which sales of the jab hit $2.39 billion, short of the company’s $2.5 billion goal.
The company said it expects manufacturing problems surrounding the vaccine to abate and for demand to rise.
Still, sales of the vaccine aren’t expected to be a large part of the company’s overall bottom line as J&J sells it at a not-for-profit price.